Investment Analysts’ Recent Ratings Updates for Belite Bio (BLTE)

Belite Bio (NASDAQ: BLTE) has recently received a number of price target changes and ratings updates:

• 8/14/2026 – Belite Bio had its price target raised by Morgan Stanley from $201.00 to $206.00. They now have an “overweight” rating on the stock.
• 8/14/2026 – Belite Bio had its “buy” rating reaffirmed by Benchmark Co..
• 8/14/2026 – Belite Bio was given a new $220.00 price target by Mizuho.
• 8/12/2026 – Belite Bio had its price target raised by Cantor Fitzgerald from $266.00 to $270.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Belite Bio had its price target raised by HC Wainwright from $200.00 to $214.00. They now have a “buy” rating on the stock.
• 7/22/2026 – Belite Bio had its “buy” rating reaffirmed by HC Wainwright.
• 7/20/2026 – Belite Bio was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/6/2026 – Belite Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other Belite Bio news, CFO Hao-Yuan Chuang sold 367 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total value of $66,188.45. Following the sale, the chief financial officer directly owned 93,433 shares in the company, valued at $16,850,641.55. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Hendrik Peter Scholl sold 10,000 shares of the company’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $145.24, for a total value of $1,452,400.00. Following the transaction, the insider directly owned 15,000 shares in the company, valued at $2,178,600. This represents a 40.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 20,732 shares of company stock valued at $2,990,116 over the last ninety days. 13.29% of the stock is currently owned by insiders.

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.